ADMELOG<sup>®</sup> may be covered under Managed Medicaid in your state. Find out below:

Please check directly with the health plan to confirm coverage.

Powered by Managed Markets Insight & Technology, LLC. Database current as of December, 2024.

© 1998-2019 Managed Markets Insight & Technology, LLC. All rights reserved.

Admelog savings for eligible patients with and without prescription insurance*

Support Resources for Commercial Patients - $35* Co-Pay Offer

  • Eligible commercially insured patients pay no more than $35 per 30-Day Supply. Valid up to 10 packs per fill.
    *See Terms and Eligibility Restrictions
  • Offer valid for Admelog Solostar pens and Admelog vials

Your patients can learn more by visiting Admelog.com

For Patients Without Prescription Insurance or Commercially Insured Patients Paying Cash.

  • Your uninsured or cash paying patients pay $35* per 30 Day Supply of any one or combination of Sanofi Insulins, including Admelog.
    *See Terms and Eligibility Restrictions
  • Patients must fill all their Sanofi Insulin prescriptions at the same time, together each month.

*See Terms and Eligibility Restrictions  

Need help? Call 855-443-1577 and press # for agent 8AM - 8PM ET M-F (except holidays)

If your patients need additional financial assistance, click here.

Learn more about Savings Offers on other Sanofi Insulins.

Sanofi Patient Connection logo

Sanofi Patient Connection®

Sanofi Patient Connection is a program designed to assist patients with three main types of patient support:

  • Reimbursement Connection: Supports you in determining your insurance coverage for Sanofi medications
  • Patient Assistance Connection: Helps provide certain Sanofi prescription medications at no cost if you meet program eligibility requirements
  • Resource Connection: Identifies additional resources and support that patients might find helpful

Highly Similar to Humalog®

In structure and pharmacology1,2

Resources Available

Download clinical publications and resources for patients and pharmacists

Indication for ADMELOG® (insulin lispro injection) 100 Units/mL

ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes and adults and children (3 years and older) with type 1 diabetes.

Important Safety Information

Important Safety Information

CONTRAINDICATIONS

ADMELOG is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin lispro or to any of its excipients.

WARNINGS AND PRECAUTIONS

Insulin pens and needles must never be shared between patients, even if the needle is changed. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Hypoglycemia is the most common adverse reaction associated with insulins, including ADMELOG, and may be life-threatening.

Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between ADMELOG and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including ADMELOG. If hypersensitivity reactions occur, discontinue ADMELOG, treat per standard of care and monitor until symptoms and signs resolve.

All insulin products, including ADMELOG, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia.

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs.

ADVERSE REACTIONS

Adverse reactions associated with ADMELOG include hypoglycemia, hypokalemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine).

IMPORTANT SAFETY INFORMATION FOR ADMELOG® (INSULIN LISPRO INJECTION) SOLOSTAR®

ADMELOG SoloStar is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels.

IMPORTANT SAFETY INFORMATION FOR ADMELOG® (INSULIN LISPRO INJECTION) USE IN PUMP

Pump failure or insulin infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Prompt identification and correction of the cause is necessary. Interim subcutaneous injections with ADMELOG may be required. Patients using a pump must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

Click here for Full Prescribing Information.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

 

*Eligibility Restrictions & Offer Terms for your Patients:

Insulins Valyou Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. The Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Insulins Valyou Savings Program at (833) 813-0190(833) 813-0190 (8:00 am-8:00 pm EST, Monday-Friday).

Sanofi Insulins Co-pay Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Sanofi Insulins Co-pay Savings Program at (866) 255-8661(866) 255-8661 (8:00 am-8:00 pm EST, Monday-Friday).

References:

1. ADMELOG Prescribing Information.
2. Humalog Prescribing Information.

 

Important Safety Information

Important Safety Information

CONTRAINDICATIONS

ADMELOG is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin lispro or to any of its excipients.

WARNINGS AND PRECAUTIONS

Insulin pens and needles must never be shared between patients, even if the needle is changed. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Hypoglycemia is the most common adverse reaction associated with insulins, including ADMELOG, and may be life-threatening.

Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between ADMELOG and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including ADMELOG. If hypersensitivity reactions occur, discontinue ADMELOG, treat per standard of care and monitor until symptoms and signs resolve.

All insulin products, including ADMELOG, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia.

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs.

ADVERSE REACTIONS

Adverse reactions associated with ADMELOG include hypoglycemia, hypokalemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine).

IMPORTANT SAFETY INFORMATION FOR ADMELOG® (INSULIN LISPRO INJECTION) SOLOSTAR®

ADMELOG SoloStar is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels.

IMPORTANT SAFETY INFORMATION FOR ADMELOG® (INSULIN LISPRO INJECTION) USE IN PUMP

Pump failure or insulin infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Prompt identification and correction of the cause is necessary. Interim subcutaneous injections with ADMELOG may be required. Patients using a pump must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

Click here for Full Prescribing Information.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

 

*Eligibility Restrictions & Offer Terms for your Patients:

Insulins Valyou Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. The Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Insulins Valyou Savings Program at (833) 813-0190(833) 813-0190 (8:00 am-8:00 pm EST, Monday-Friday).

Sanofi Insulins Co-pay Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Sanofi Insulins Co-pay Savings Program at (866) 255-8661(866) 255-8661 (8:00 am-8:00 pm EST, Monday-Friday).

References:

1. ADMELOG Prescribing Information.
2. Humalog Prescribing Information.